This is a monocenter, open-label, uncontrolled study in accordance with §23b MPG to evaluate the efficacy of the HIFU-treatment of fibroadenoma using the TH-One device.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
27
Department for Women's Health
Tübingen, Germany
The efficacy is assessed by a reduction in volume of the fibroadenoma at baseline, 6 months and at 12 months after the HIFU on the ultrasonography.
A reduction in volume of \> 65% compared to baseline, or a total regression of the fibroadenoma will be taken as effective treatment. The results will be analyzed descriptively
Time frame: Baseline, 6 months, 12 months
Energy setting to obtain reduction in volume or total regression of the fibroadenoma at 12 months follow-up
Time frame: 1 year
Lack of palpable lesion
Time frame: 2 years
Pain free if pain at baseline (pain related to the fibroadenoma)
Time frame: 1 year
Gland vascularisation (compared to baseline) power Doppler at day 7, month 6 and 12 after the HIFU session
Time frame: Day 7, month 6, month 12
Pain during the HIFU session using a Visual Analog Pain Scale
Time frame: 0 month
Histological outcome through core needle biopsy after 12 month
Time frame: 1 year
Quality and ease of use of breast immobilization
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.